##plugins.themes.bootstrap3.accessible_menu.label##
  • ##plugins.themes.bootstrap3.accessible_menu.main_navigation##
  • ##plugins.themes.bootstrap3.accessible_menu.main_content##
  • ##plugins.themes.bootstrap3.accessible_menu.sidebar##
  • Submit
  • Register
  • Login
  • Home
  • Press
  • Issues
  • Submissions
  • Editorial Board
  • News
  • About
  1. Home /
  2. Archives /
  3. Vol. 2 No. 1 (2023)

Vol. 2 No. 1 (2023)

					View Vol. 2 No. 1 (2023)
Published: 2023-06-14

Review Article

  • Unravelling the application of machine learning in cancer biomarker discovery

    Carter William, Choki Wangmo, Anjali Ranjan
    1-8
    • PDF
  • Liver fibrosis from viral hepatitis: advances in non-invasive diagnosis

    Jincheng Wang, Jinyu Sun, Tao Qin, Xiaohan Ren, Jin Zhang, Xiaojie Lu
    9-30
    • PDF
  • Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics

    Fatemeh Movahedi , Li Li, Zhiping Xu
    31-52
    • PDF
  • Role of macrophage polarization in cancer progression and their association with COVID-19 severity

    Abhimanyu Thakur, Rumpa Banerjee, Sudha Thakur, Gaurav Kumar, Shyam Sundar Thakur
    68-79
    • PDF
  • Advances in the Use of Nanomaterials in Tumour Therapy: Challenges and Prospects

    Hongmei Yang, Chen Li, Qiang Xie
    80-101
    • PDF
  • E3 ubiquitin ligase-dependent regulatory mechanism of TRIM family in carcinogenesis

    Gui Zhang, Yunfang Zhang, Luxuan Chen, Langxia Liu, Xuejuan Gao
    102-130
    • PDF
  • Cell membrane-coated nanoparticles for cancer therapy

    Yasir Hameed, Mohsen Nabi-Afjadi, Yuan Gu, Long Wu
    145-162
    • PDF

Articles

  • Effect of interleukin-8 on docetaxel resistance in prostate cancer cells: insights into the role of multidrug resistance 1 protein modulation

    Suleyman ILHAN
    53-67
    • PDF
  • Mechanism of congenital lymphocytes and intestinal immunity regulated by gut microbial metabolites via metabolite-sensing receptor Ffar2

    Chen Deng
    131-144
    • PDF

Visit our new website!

Call for Editorial Board Members for CI

2022-12-15

Editor-in-Chief: Dr. Zhiping Xu

Frequency: Half-yearly

Time to first decision: 2.4 Weeks

Submission to publication: 4 Weeks

ISSN: 2972-3388

Make a Submission

Make a Submission

Open Access Statement  |  Privacy Statement  |  Copyright Policy  | Publishing Ethics | Archiving Policy | Crossmark Policy | Revenue Sources | Contact Information

Contact Email: CancerInsight@anser.press  |  ISSN: 2972-3388  |  © 2020-2023 Anser Press Pte.Ltd. All rights reserved 

Indexed by

                                         

Published by